when will glp-1 become generic Cipla USA Inc. Launches Saxenda® in the U.S., Expanding Access to Weight Management Therapy The @U.S. Food and Drug

Int J Mol Sci (2019) 20(8):1940

Tirzepatide typically produces greater weight loss

B., Lamark, T

Side-by-Side: Clinical Considerations AttributeWeekly Agents (Semaglutide, Dulaglutide, Exenatide ER)Daily / Twice-Daily Agents (Liraglutide, Exenatide IR, Lixisenatide) Convenience & Adherence High fewer injections to missLower daily or twice daily schedules Weight Loss Potential Semaglutide typically wins Usually more modest weight loss Gastrointestinal Side Effects Common, especially during up-titrationSame class risks, often more noticeable with frequent dosing Clinical Experience / Track Record S emaglutide is newer but well studied

So the question to me, there's two questions practically

Because of the safety concerns and lack of approval, it should be approached with caution and medical guidance